전립선암
Men with "BRCA" mutations cannot get ovarian cancer, but they may be twice as likely as non-carriers to develop prostate cancer at a younger age. The risk is smaller and disputed for "BRCA1" carriers; up to one-third of "BRCA2" mutation carriers are expected to develop prostate cancer before age 65. Prostate cancer in "BRCA" mutation carriers tends to appear a decade earlier than normal, and it tends to be more aggressive than normal. As a result, annual prostate screening, including a digital rectal examination, is appropriate at age 40 among known carriers, rather than age 50.